Stryker has announced the availability of the Surpass Evolve flow diverter following CE-mark approval in March. Surpass Evolve is Stryker’s latest entrant into the flow diversion space for the treatment of brain aneurysms.
After conducting first clinical procedures, Vitor Mendes Pereira (Toronto Western Hospital, Toronto, Canada) stated: “Surpass Evolve represents an exciting advancement in the treatment of complex brain aneurysms. The device is easy to use, highly responsive and demonstrates a strong flow diversion for aneurysm healing.”
A Stryker press release notes that, building on the reliable opening and optimised flow diversion profile of the existing Surpass platform, this new device has been designed to maximise overall procedural ease of use and provide physicians with a high level of control through the procedure.
“The Surpass Evolve flow diverter is the culmination of many years of flow diversion research, extensive physician feedback from around the world and Stryker engineering prowess. This high-performing device will be a great addition to our haemorrhagic portfolio to help physicians in the treatment of brain aneurysms,” said Mark Paul, president, Stryker’s Neurovascular division.
Usage of flow diversion technology for the treatment of brain aneurysms has grown in acceptance and significance over the last decade, the release continues, also referring to the fact that flow diverters enable physicians to treat their patients suffering from brain aneurysms without ever entering the sac of the aneurysm itself.
